盆腔肿瘤放化疗与骨髓抑制相关性的研究进展

局部进展期和中晚期直肠癌、宫颈癌患者的主要治疗手段为同步放化疗。骨盆是全身造血骨髓分布比例最大的区域，也是盆腔肿瘤患者放疗时无法避免的区域。同步放化疗在提高疗效的同时也增加了血液毒性的发生率，一旦出现严重骨髓抑制，会导致治疗中断，延长治疗时间，最终可能影响疗效。骨髓抑制风险识别是肿瘤放化疗治疗中亟须解决的一个重要问题。该文从放疗技术、放疗剂量学参数和化疗方案等方面对国内外肿瘤放化疗与骨髓抑制相关性的研究现状进行综述，为构建我国骨髓抑制预测模型提供参考，以便早期识别高危人群，进行针对性的预防和治疗。

Research progress of the correlation between radiotherapy and chemotherapy and bone marrow suppression in pelvic tumors

Concurrent radiotherapy and chemotherapy is the main treatment for patients with rectal cancer and cervical cancer during locally advanced and middle to advanced. The pelvis is the largest proportion of hematopoietic bone marrow in the whole body, and it is an unavoidable area of radiotherapy for pelvic tumor patients. Concurrent radiotherapy and chemotherapy can improve the curative effect, but also increase the incidence of hematologic toxicity. Once severe bone marrow suppression occurs in concurrent radiotherapy and chemotherapy, the treatment will be interrupted, the time of treatment will be prolonged, and ultimately affect the curative effect. Bone marrow suppression risk identification are the important issues that need to be solved in the tumor radiation and chemotherapy treatment. This paper reviewed the research status of the correlation between radiotherapy and chemotherapy and bone marrow suppression in pelvic tumors at home and abroad from the aspects of radiotherapy technology, radiotherapy dosimetry parameters, chemotherapy regimens and so on. We aimed to provide reference for the construction of a prediction model of bone marrow suppression in our country, in order to identify high-risk groups early, formulate prevention and treatment.